Progress of molecular targeted therapies for advanced renal cell carcinoma.

Biomed Res Int · 2013 · PMC3777192 · PMID 24093097

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

While the progression-free survival was improved, the overall survival (OS) showed a trend toward a detrimental effect with the tivozanib arm with a median OS of 28.8 months versus 29.3 months in the sorafenib arm based on the pre-new drug application (NDA) meeting with the US Food and Drug Administration (FDA) [ 29 ] which later led to the FDA ODAC meeting to disapprove tivozanib as an indication for RCC.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.